Sun Pharma Advanced Research Company Ltd. has successfully confirmed the receipt of funds toward the preferential allotment of 3,85,10,000 convertible warrants. The company received a total consideration of Rs. 149,99,64,500 from Shanghvi Finance Private Limited. This transaction was finalized on May 19, 2026, and is supported by certification from the company’s statutory auditors, ensuring full compliance with the mandated financial disclosure standards for such preferential issues.
Transaction Overview
Sun Pharma Advanced Research Company Ltd. has completed the formal process regarding the receipt of subscription funds for its recent preferential allotment. The allotment involves 3,85,10,000 convertible warrants, each issued at a price of Rs. 155.80. The total amount processed for this transaction stands at Rs. 149,99,64,500.
Details of Fund Receipt
The funds were received from Shanghvi Finance Private Limited on May 19, 2026. The remittance was processed through ICICI Bank, Mumbai-Nariman Point, and has been verified by the company’s statutory auditors, S R B C & Co LLP. The audit confirms that the company has maintained all necessary documentation and is in full compliance with the requirements for preferential issues as on the date of certification, May 25, 2026.
Source: BSE
